Aarti Pharmalabs [AARTIPHARM] vs Hikal [HIKAL] Detailed Stock Comparison
Aarti Pharmalabs
NSE
Loading...
Hikal
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Aarti Pharmalabs wins in 13 metrics, Hikal wins in 6 metrics, with 0 ties. Aarti Pharmalabs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Aarti Pharmalabs | Hikal | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 30.00 | 50.73 | Aarti Pharmalabs |
| Price-to-Book Ratio | 4.01 | 2.54 | Hikal |
| Debt-to-Equity Ratio | 20.76 | 60.58 | Aarti Pharmalabs |
| PEG Ratio | -2.78 | -0.09 | Aarti Pharmalabs |
| EV/EBITDA | 17.95 | 13.28 | Hikal |
| Profit Margin (TTM) | 13.69% | 3.45% | Aarti Pharmalabs |
| Operating Margin (TTM) | 18.76% | -3.76% | Aarti Pharmalabs |
| EBITDA Margin (TTM) | 18.76% | N/A | N/A |
| Return on Equity | 13.69% | 7.19% | Aarti Pharmalabs |
| Return on Assets (TTM) | 9.37% | 3.59% | Aarti Pharmalabs |
| Free Cash Flow (TTM) | $-1.12B | $1.43B | Hikal |
| Dividend Yield | 0.40% | 0.74% | Hikal |
| 1-Year Return | 26.80% | -24.43% | Aarti Pharmalabs |
| Price-to-Sales Ratio (TTM) | 4.11 | 1.75 | Hikal |
| Enterprise Value | $83.28B | $39.49B | Aarti Pharmalabs |
| EV/Revenue Ratio | 4.28 | 2.15 | Hikal |
| Gross Profit Margin (TTM) | 56.13% | 49.69% | Aarti Pharmalabs |
| Revenue per Share (TTM) | $215 | $149 | Aarti Pharmalabs |
| Earnings per Share (Diluted) | $29.37 | $5.12 | Aarti Pharmalabs |
| Beta (Stock Volatility) | -0.50 | 0.45 | Aarti Pharmalabs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Aarti Pharmalabs vs Hikal Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Aarti Pharmalabs | 0.16% | 4.91% | 1.53% | -4.60% | 16.31% | 26.21% |
| Hikal | 0.90% | 2.78% | -17.07% | -30.05% | -27.51% | -34.94% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Aarti Pharmalabs | 26.80% | 240.13% | 240.13% | 240.13% | 240.13% | 240.13% |
| Hikal | -24.43% | -23.07% | 67.37% | 279.14% | 316.63% | 213.33% |
Performance & Financial Health Analysis: Aarti Pharmalabs vs Hikal
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Market Information | ||
| Market Cap | ₹83.46B | ₹32.33B |
| Market Cap Category | Mid cap | Small cap |
| 10 Day Avg. Volume | 253,325 | 791,023 |
| 90 Day Avg. Volume | 353,028 | 508,834 |
| Last Close | ₹882.65 | ₹262.10 |
| 52 Week Range | ₹557.05 - ₹971.00 | ₹245.00 - ₹464.75 |
| % from 52W High | -9.10% | -43.60% |
| All-Time High | ₹971.00 (Jul 16, 2025) | ₹742.00 (Aug 16, 2021) |
| % from All-Time High | -9.10% | -64.68% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.31% | -0.07% |
| Quarterly Earnings Growth | -0.11% | -0.08% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.03% |
| Operating Margin (TTM) | 0.19% | -0.04% |
| Return on Equity (TTM) | 0.14% | 0.07% |
| Debt to Equity (MRQ) | 20.76 | 60.58 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹219.62 | ₹102.34 |
| Cash per Share (MRQ) | ₹6.20 | ₹1.46 |
| Operating Cash Flow (TTM) | ₹3.51B | ₹1.54B |
| Levered Free Cash Flow (TTM) | ₹2.72B | ₹908.00M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.40% | 0.74% |
| Last 12-Month Dividend | ₹3.50 | ₹2.00 |
Valuation & Enterprise Metrics Analysis: Aarti Pharmalabs vs Hikal
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 30.00 | 50.73 |
| Forward P/E | N/A | 20.21 |
| PEG Ratio | -2.78 | -0.09 |
| Price to Sales (TTM) | 4.11 | 1.75 |
| Price to Book (MRQ) | 4.01 | 2.54 |
| Market Capitalization | ||
| Market Capitalization | ₹83.46B | ₹32.33B |
| Enterprise Value | ₹83.28B | ₹39.49B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.28 | 2.15 |
| Enterprise to EBITDA | 17.95 | 13.28 |
| Risk & Other Metrics | ||
| Beta | -0.50 | 0.45 |
| Book Value per Share (MRQ) | ₹219.62 | ₹102.34 |
Financial Statements Comparison: Aarti Pharmalabs vs Hikal
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AARTIPHARM | HIKAL |
|---|---|---|
| Revenue/Sales | ₹5.64B | ₹5.50B |
| Cost of Goods Sold | ₹2.79B | ₹2.32B |
| Gross Profit | ₹2.85B | ₹3.18B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.23B | ₹857.00M |
| EBITDA | ₹1.44B | ₹1.24B |
| Pre-Tax Income | ₹1.15B | ₹683.00M |
| Income Tax | ₹262.81M | ₹181.00M |
| Net Income (Profit) | ₹883.39M | ₹502.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AARTIPHARM | HIKAL |
|---|---|---|
| Cash & Equivalents | ₹67.34M | ₹130.00M |
| Total Current Assets | ₹13.22B | ₹9.95B |
| Total Current Liabilities | ₹6.57B | ₹7.90B |
| Long-Term Debt | ₹1.15B | ₹3.70B |
| Total Shareholders Equity | ₹19.90B | ₹12.62B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹11.04B | ₹13.57B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AARTIPHARM | HIKAL |
|---|---|---|
| Operating Cash Flow | ₹522.01M | N/A |
| Capital Expenditures | ₹-331.51M | N/A |
| Free Cash Flow | ₹702.37M | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 253,325 | 791,023 |
| Average Daily Volume (90 Day) | 353,028 | 508,834 |
| Shares Outstanding | 90.63M | 123.30M |
| Float Shares | 47.97M | 38.11M |
| % Held by Insiders | 0.45% | 0.69% |
| % Held by Institutions | 0.11% | 0.08% |
Dividend Analysis & Yield Comparison: Aarti Pharmalabs vs Hikal
| Metric | AARTIPHARM | HIKAL |
|---|---|---|
| Last 12-Month Dividend | ₹3.50 | ₹2.00 |
| Last 12-Month Dividend Yield | 0.40% | 0.74% |
| 3-Year Avg Annual Dividend | ₹2.11 | ₹1.40 |
| 3-Year Avg Dividend Yield | 0.24% | 0.20% |
| 3-Year Total Dividends | ₹6.34 | ₹4.20 |
| Ex-Dividend Date | Feb 14, 2025 | Sep 02, 2025 |